Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic bevacizuma...
Leadership
Robert Charles Jahr
President, CEO & Director
Lawrence A. Kenyon CPA
EVP, CFO, Treasurer, Secretary & Director
Joel Prieve
Senior Vice President of Licensing and M&A
Surendra Sharma M.D.
Senior Vice President of Medical Affairs
Jennifer M. Kissner Ph.D.
Senior Vice President of Clinical Development & Regulatory Affairs
